Abiomed has quickly climbed our Big 100 list, landing this year at 90th, and it has done so without major acquisitions. Fueling the global medtech company’s growth is a device with unique indications and a patient-centered business strategy. More than 60,000 patients have been treated using Abiomed’s (NSDQ:ABMD) Impella heart pumps – and every time the […]
Featured
Smart bandage releases medication as needed
A team of researchers from the University of Nebraska, Harvard Medical School and MIT have created a smart bandage that can be loaded with antibiotics, painkillers or other drugs and triggered by a smartphone. The bandage, made of electrically conductive fibers individually coated in a drug-loaded hydrogel, could be used to deliver multiple drugs at […]
Azura Ophthalmics raises $16m for meibomian gland dysfunction therapy
Biotech Azura Ophthalmics said today that it closed a $16 million Series B round led by a syndicate of OrbiMed, TPG Biotech and Brandon Capital’s Medical Research Commercialization Fund. Existing investor Ganot Capital also participated in the round. The investment is slated to support Azura’s development of a drug for a leading cause of dry […]
Tandem shareholders approve 1-for-10 reverse split
Tandem Diabetes Care (NSDQ:TNDM) shareholders have approved a 1-for-10 reverse stock split, the company said earlier this week, which took effect today. In a statement filed with the SEC in July, the San Diego, Calif.-based company told shareholders that it believed a reverse stock split would help Tandem keep its common stock listed on the Nasdaq […]
Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding […]
Intersect ENT touts results from pivotal study of steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) touted data this week from the pivotal Resolve II trial of its investigational steroid-releasing sinus implant, Sinuva. The Phase III trial evaluated Sinuva in 300 adult chronic sinusitis patients, who were all indicated for revision sinus surgery at study entry due to recurrent, medically refractory symptoms and bilateral nasal polyposis. Study participants were […]
Biotronik launches trial to test new coronary drug-eluting stent
Biotronik said yesterday that it began enrolling patients in a trial designed to assess the safety and efficacy of a new coronary drug-eluting stent in de novo coronary artery lesions. The Biovitesse polymer-free device combines ultra-thin struts with a new anti-proliferative limus drug designed to stop excessive cell growth, the company reported. In September, Dr. […]
Insulet looks to lure Animas users
Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]
India pulls an about-face on Abbott’s Xience Alpine stent
India’s Department of Pharmaceuticals has stopped Abbott (NYSE:ABT) from pulling its Xience Alpine drug-eluting coronary stent from the market. The move is a reversal from the National Pharmaceutical Pricing Authority’s decision last month to allow Abbott to withdraw the device over a one-year period. Last week, the DoP said it invoked powers described in the Drug […]
MiMedx closes Stability Biologics sale
MiMedx (NSDQ:MDXG) said this week that it completed the divestiture of its subsidiary, Stability Biologics, back to the former stockholders of Stability, Inc. The deal, which closed on Sept. 30, included a promissory note issued by Stability Biologics for $3.5 million in favor of MiMedx. “When we signed the definitive agreement for the divestiture, we communicated […]